Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Related Keywords

,Recent Updates ,Translating Evidence ,Clinical Practice ,Unresectable Stage ,Nsclc ,Early Nsclc ,Non Small Cell Lung Cancer ,Asco 2023 ,Localized Disease ,Presection ,Surgery ,Staging ,Chemoimmunotherapy ,Immunotherapy ,Ohio ,Molecular Testing ,Liquid Biopsy ,Tissue Biopsy ,Ngs Testing ,Egfr ,Talk ,